Allkem General Discussion, page-3435

Just got this in an email ...Fri, 21 Apr at 9:36 am

Friday, 21 April 2023

AKE - ALLKEM LIMITED

Macquarie rates AKE as Outperform (1) - Allkem's March quarter result was mixed, Macquarie notes, with higher-than-expected production offset by lower shipments. June quarter lithium pricing guidance was also mixed, on weaker carbonate pricing meeting spodumene prices largely in line with forecasts.

Target falls to $16.70 from $17.00, Outperform retained. The broker awaits updates on developments at Sal de Vida, Olaroz and James Bay, which present key near-term catalysts.

Target price is $16.70 Current Price is $11.64 Difference: $5.06 If AKE meets the Macquarie target it will return approximately 43% (excluding dividends, fees and charges). Current consensus price target is $16.04, suggesting upside of 37.8%(ex-dividends)The company's fiscal year ends in June.

Forecast for FY23:

Macquarie forecasts a full year FY23 dividend of 0.00 cents and EPS of 68.40 cents . At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 17.02. How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 88.0, implying annual growth of 23.7%. Current consensus DPS estimate is N/A, implying a prospective dividend yield of N/A. Current consensus EPS estimate suggests the PER is 13.2.

Forecast for FY24:

Macquarie forecasts a full year FY24 dividend of 0.00 cents and EPS of 157.80 cents . At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 7.38. How do these forecasts compare to market consensus projections?

Current consensus EPS estimate is 129.6, implying annual growth of 47.3%. Current consensus DPS estimate is 6.7, implying a prospective dividend yield of 0.6%. Current consensus EPS estimate suggests the PER is 9.0.

Market Sentiment: 1.0All consensus data are updated until yesterday. FNArena's consensus calculations require a minimum of three sources